KRAS and colorectal carcinoma: Our understanding of resistance mechanisms to KRAS inhibitors in PDAC remains limited and stems primarily from patients with NSCLC, CRC, and PDAC who have been treated with KRASG12C-selective inhibitors (87, 88, 164–167).